Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950733 | 0.89 | CHRM2 (0.44) | CHRM2CHRM1CHRM3KDM4EPKM | |
| SCHEMBL24024276 | 0.89 | CHRM2 (0.44) | CHRM2CHRM1CHRM3KDM4EPKM | |
| SCHEMBL29217067 | 0.84 | TACR1 (0.34) | CHRM2CHRM1CHRM3BTKKDM4E | |
| SCHEMBL2360394 | 0.81 | GABRA1 (0.35) | — | |
| SCHEMBL30218180 | 0.80 | GBA2 (0.36) | CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL30129954 | 0.79 | HSD17B10 (0.37) | HSD17B10SMN1; SMN2 | |
| SCHEMBL23950879 | 0.77 | CHRM2 (0.35) | CHRM2CHRM1CHRM3 | |
| SCHEMBL25214699 | 0.74 | SMN1; SMN2 (0.34) | BTKKDM4EPKMHSD17B10SMN1; SMN2 | |
| SCHEMBL25284095 | 0.74 | SMN1; SMN2 (0.34) | BTKKDM4EPKMHSD17B10SMN1; SMN2 | |
| SCHEMBL24540373 | 0.74 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4367117-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230143938-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023056421-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230056631-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| EP-4135844-A1 | FUSED TRICYCLIC KRAS INHIBITORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023283213-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056631-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4864/4885CHRM1 4858/4885CHRM3 4857/4885 |
| US-20230143938-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4856/4885CHRM1 4850/4885CHRM3 4832/4885 |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885 |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4866/4885CHRM1 4851/4885CHRM3 4871/4885 |
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | KRAS, NRAS, HRAS | CHRM2 4856/4885CHRM1 4850/4885CHRM3 4832/4885 |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4875/4885CHRM1 4872/4885CHRM3 4867/4885 |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.